Improving the efficiency of gene insertion in a human artificial chromosome vector and its transfer in human-induced pluripotent stem cells

Yoshinori Hasegawa1,*, Masashi Ikeno2, Nobutaka Suzuki3, Manabu Nakayama4 and Osamu Ohara1

1Laboratory of Clinical Omics Research, Department of Applied Genomics, Kazusa DNA Research Institute, Chiba, Japan; 2Aichi Medical University, Aichi, Japan; 3Chromoresearch Inc., Aichi, Japan and 4Laboratory of Medical Omics Research, Department of Frontier Research and Development, Kazusa DNA Research Institute, Chiba, Japan

*Correspondence address: Laboratory of Clinical Omics Research, Department of Applied Genomics, Kazusa DNA Research Institute, Chiba, Japan. Tel: +81 438 52 3944; Fax: +81 438 52 3921; E-mail: yhasega@kazusa.or.jp

Abstract

A human artificial chromosome (HAC) vector has potential to overcome the problems of stable gene expression associated with plasmid, transposon, and virus-based vectors, such as insertional mutagenesis, position effect, uncontrollable copy number, unstable gene expression, and DNA size limitation. The main advantages of the HAC are its episomal nature and ability to accommodate DNA inserts of any size. However, HAC vectors have two disadvantages: low efficiency of gene insertion and lack of reports regarding the successful HAC transfer to human-induced pluripotent stem cells (iPSCs). We here provide the first report of a method for the efficient transfer of HAC to human iPSCs for obtaining reproducible experimental results. Moreover, we achieved a 10% increase in the gene insertion efficiency in the HAC vector using our new site-specific recombination systems VCre/VloxP and SCre/SloxP.

Keywords: Human artificial chromosome (HAC) vector, hiPSC, dual RMCE

Introduction

Human-induced pluripotent stem cells (iPSCs) generated from the somatic cells of patients and donors provide new opportunities for research on human cell biology and disease modeling [1]. The ability of disease-specific iPSCs to differentiate into affected tissues can be used for in vitro disease modeling and development of cell therapeutics. Recent advancements in genome editing technology have considerably expanded the application of human iPSCs in disease modeling, drug testing, and screening, as well as in research on human cell biology [2, 3]. Knocking out genes in human iPSCs via genome editing, followed by inducible expression of transgenes such as variants of disease-associated genes are fairly effective strategies for understanding disease pathogenesis [4]. Virus and transposon-based vectors are most commonly used for the genetic manipulation of human iPSCs, although they are associated with several problems such as insertional mutagenesis, position effect, uncontrollable copy number, unstable gene expression, and DNA size limitation. Recently, the AAVS1 locus, a "safe-harbor" site with an open chromosomal region, has become more widely utilized as a transgene-targeting site in human iPSCs using transcription activator-like effector nuclease
(TALEN) or clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and reportedly showed stable transgene expression [5, 6]. Although the copy number of the transgene can be controlled and stable expression can be achieved, off-target cleavage is a potential drawback of these technologies.

As an alternative, human artificial chromosome (HAC)-based vectors are promising tools for overcoming the aforementioned problems associated with viral and non-viral vectors. HACs can be engineered using “top-down” [7] and “bottom-up” approaches [8, 9]. Using a bottom-up approach, we previously developed a HAC vector system in which one copy of the DNA fragment of interest can be manipulated by a Cre/lox insertion in any cell line of interest [10]. We used this system and the long interspersed nuclear elements 1 family of transposons to regulate chromatin [11], and developed a transgenic mouse harboring a HAC with a single copy of three human genes encoding cystathionine beta synthase, U2 auxiliary factor 1, and crystalline alpha A [12], respectively. We also established another transgenic mouse strain using this approach that retained multiple independent BAC transgenes [13].

Although several studies on HAC vectors have been reported [14, 15], two aspects need to be addressed for improving the features of HACs as gene expression vectors. First, to our knowledge, HAC transfer in human pluripotent stem cells such as human embryonic stem (hES) cells and hiPSCs has not been achieved to date, although one of the most suitable application areas of the HAC vector is gene therapy [16–18]. Second, although Cre recombinase-mediated cassette exchange (RMCE) utilizes the ability of site-specific recombinases to replace a HAC gene insertion site with a DNA fragment of interest, the gene insertion efficiency in the HAC vector is extremely low (10<sup>-3</sup>–10<sup>-5</sup>) [10, 13]. This efficiency is sufficient for generating an insertional clone of a gene of interest in the HAC vector using drug selection; however, construction of several clones for screening experiments using many plasmids at one Cre/lox recombinase site is challenging. To solve the second problem, Anderson et al. [19] reported that the optimal configuration of flp and cre showed the highest level of dual RMCE (35–45% of plasmid-transfected cells). In contrast, our group developed two new site-specific recombination systems (VCre/Vlox<sup>P</sup> and SCre/Slox<sup>P</sup>) for genome engineering [20]. These systems do not cross-react with the Cre/lox<sup>P</sup> and Flp/FRT systems, and therefore all systems can be used together within the same cell. We attempted to use the VCre/Vlox<sup>P</sup> and SCre/Slox<sup>P</sup> systems, along with the Cre/lox<sup>P</sup> and Flp/FRT systems, for dual RMCE. To address the first problem, an improved microcell-mediated chromosome transfer (MMCT) method of higher efficiency was recently reported [21]. MMCT enables a single intact mammalian chromosome or an autonomous megabase-sized chromosome fragment to be transferred from the donor to recipient cell lines. The maximum increase in MMCT efficiency obtained was approximately 6-fold when using colcemid and cytochalasin B with TN-16-griseofulvin, and latrunculin B in combination with a collagen/laminin surface coating.

In this study, we aimed to solve these two major drawbacks limiting the utilization of HAC by using the VCre/Vlox<sup>P</sup> and SCre/Slox<sup>P</sup> system and improving the MMCT technique. This approach provides a novel platform for an effective transgene-expression system in human iPSCs.

**Materials and methods**

**Cell culture**

Human epithelial kidney (HEK)293 and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Wako, Japan) supplemented with 10% fetal bovine serum (FBS) at 37°C and in an atmosphere of 5% CO<sub>2</sub>. Chinese hamster ovary (CHO) cells were maintained in Ham’s F-12 (Wako, Japan) with 10% FBS at 37°C in the presence of 5% CO<sub>2</sub>. The hiPSC line HPS0006, generated from skin tissue [22], was provided by the RIKEN BRC through the Project for Realization of Regenerative Medicine and the National Bio-Resource Project of the MEXT, Japan. The hiPSCs were maintained on iMatrix-511 (Nippi, Japan)-coated culture dishes in serum-free StemFit AK02N medium (Reprocell, Japan) at 37°C in the presence of 5% CO<sub>2</sub>.

**HAC vectors**

The HAC vectors used in this study had multiple gene-expression cassettes, which were all constructed equally [10]: the expression cassettes consisted of a CAG promoter-driven neomycin resistance gene with mutant loxP, lox71, and human beta-globin 5’HS5 and 3’HS1 sites, which functioned as insulators [23] (Fig. 1A). We compared the dual RMCE efficiency among three DsRed-expressing cassettes: FRT-DsRed-loxP, Vlox-DsRed-Slox, and Vlox-DsRed-Vlox2272 (Fig. 1B). Vlox2272 is a mutant version of Vlox<sup>P</sup>, and the two do not cross-react although VCre recombinases at both sites, which enables simultaneous use of the VCre/Vlox<sup>P</sup> and Cre/lox<sup>P</sup> systems within the same cell. Previously, Anderson et al. [19] compared the efficiency of dual RMCE using Flp and Cre among the following four configurations of transcription units: (i) flp and cre expressed as individual transcription units located on different vectors, (ii) flp and cre expressed as individual transcription units located on the same vector, (iii) flp and cre expressed from a single promoter and separated by an internal ribosome entry sequence, and (iv) flp and cre coding sequences separated by the 2A peptide and expressed as a single gene. They found that the Flp-2A-Cre plasmid driven by a single CMV promoter showed the highest efficiency. Considering these results, we constructed a CMV-Scre/2A-VCre plasmid for dual RMCE of the Slox-DsRed-Vlox cassette (Fig. 1B).

**Ethical approval**

This study was approved by the Ethics Committee of the Kazusa DNA Research Institute.

**DsRed-expressing cassette insertion in the HAC vector**

We constructed the DsRed-expressing cassettes, EGFP-cassettes, and recombinase plasmids by gene synthesis (Fig. 1A and B). For insertion of the DsRed-expressing cassettes into the HAC vector, 4μg DsRed-expressing cassette was co-transfected with 1μg CAGGS-Cre into 80%-confluent HEK293 or CHO cells containing the HAC vector in a 6-cm dish using FuGENE HD (Promega, Madison, WI) according to the manufacturer’s instructions. HEK293 or CHO cell lines were selected using 18μg/ml or 5μg/ml blasticidin S (Wako, Japan), respectively.

**Dual RMCE**

Dual RMCE reactions were performed in accordance with the methods described by Anderson et al. [19]. Two micrograms of EGFP cassettes and 0.4μg recombinase plasmids were co-transfected into the 80%-confluent cells on 6-well plates using Trans-IT 293 (Mirus, Madison, WI) according to the manufacturer’s instructions. The transfection efficiency of plasmids in HEK293 cells was estimated separately by transfecting the cells with a CMVpromoter-driven EGFP plasmid, and then the number of green fluorescent cells was counted. One-sixth of the cells
Gene insertion efficiency in HAC | 3

co-transfected with the reporters and the expression vectors were transferred to a 6-well plate 24 h post-transfection, and the green fluorescent cells were counted 48 h post-transfection.

**Isolated metaphase chromosome transfection**

Isolated metaphase chromosome transfection (iMCT) from CHO cells to HEK293T cells (Fig. 2B) was performed as described previously [24]. In brief, 70%-confluent CHO cells cultured on eight 10-cm dishes were arrested in metaphase using 0.1 g/ml colcemid (0.05 mg/ml blasticidin S). The collected cells were incubated in serum-free DMEM containing cytochalasin B (20 µg/ml) for 5 min at 37°C, followed by addition of an equal volume of Percoll (Amersham Biosciences, CA, USA). The suspension was centrifuged in a Hitachi R20A2 rotor at 15,000 rpm for 90 min at 37°C. The collected microcells containing the HAC were mixed with hiPSCs from four 10-cm dishes and centrifuged at 2000 rpm for 5 min. The pellet was suspended in 1 ml 50% PEG1500 (Roche) and incubated at room temperature for 90 s. The fused cells were washed twice and plated onto iMatrix-511-coated 10-cm dishes. hiPSCs containing the HAC were selected using 40 µg/ml G418 (Roche). The collected microcells containing the HAC were mixed with 1 ml 50% PEG1500 (Roche) and incubated at room temperature for 90 s. The fused cells were washed twice and plated onto iMatrix-511-coated 10-cm dishes. hiPSCs containing the HAC were selected using 40 µg/ml G418 (Roche). The key difference between our usual MMCT and our improved MMCT is the use of TN-16 (160 µM, Santa Cruz, CA, USA) instead of colcemid for cell synchronization at metaphase [21].

**Fluorescent in situ hybridization**

Metaphase chromosome spreads were prepared on glass slides after methanol/acetate (3:1) fixation. Fluorescent in situ hybridization (FISH) analyses were performed using pBelo-BAC DNA and 114 alphoid DNA as probes for detecting HAC vectors [25] according to conventional methods. Biotin-labeled 114 alphoid DNA was visualized using FITC-conjugated avidin (Vector Laboratories), and digoxigenin-labeled pBelo-BAC DNA was visualized using TRITC-conjugated anti-digoxigenin antibody (Roche).

**MMCT**

CHO cells were grown to 70% confluence on twenty 10-cm dishes, and then cultured for 72 h in Ham’s F-12 medium containing colcemid (0.05 µg/ml). The collected cells were incubated in serum-free DMEM containing cytochalasin B (20 µg/ml) for 5 min at 37°C, followed by addition of an equal volume of Percoll (Amersham Biosciences, CA, USA). The suspension was centrifuged in a Hitachi R20A2 rotor at 15,000 rpm for 90 min at 37°C. The collected cells were washed twice and plated onto iMatrix-511-coated 10-cm dishes. hiPSCs containing the HAC were selected using 40 µg/ml G418 (Roche). The key difference between our usual MMCT and our improved MMCT is the use of TN-16 (160 µM, Santa Cruz, CA, USA) instead of colcemid for cell synchronization at metaphase [21].

**Fluorescent in situ hybridization**

Metaphase chromosome spreads were prepared on glass slides after methanol/acetate (3:1) fixation. Fluorescent in situ hybridization (FISH) analyses were performed using pBelo-BAC DNA and 114 alphoid DNA as probes for detecting HAC vectors [25] according to conventional methods. Biotin-labeled 114 alphoid DNA was visualized using FITC-conjugated avidin (Vector Laboratories), and digoxigenin-labeled pBelo-BAC DNA was visualized using TRITC-conjugated anti-digoxigenin antibody (Roche).
**Total RNA extraction, mRNA library preparation, and 3’ RNA-seq**

It is imperative to maintain hiPSCs in an undifferentiated state without any pathogen contamination for therapeutic applications. Therefore, we compared the whole-transcriptome profiles between control iPSCs and iPSC transfectants containing HACs, with focus on the expression of pluripotent markers using 3’ RNA-seq. Total RNA was extracted from 50%-confluent cells on a 3.5-cm dish and each sample was transferred to 800 μl TRIZOL reagent (Life Technologies, Carlsbad, CA, USA). The solution was vigorously vortexed and incubated at room temperature for 5 min. The solution was then centrifuged after adding 200 μl chloroform, and the aqueous phase was carefully transferred to a new tube, following which 10 μg glycogen (Life Technologies) was added as a co-precipitant. RNA was precipitated by adding 600 μl isopropanol alcohol. The RNA pellet was washed once with 75% ethanol and then dissolved in 10 μl RNase-free water. The concentration and the quality of the RNA were verified using a Qubit fluorometer (Life Technologies) and Agilent 2100 bioanalyzer, respectively. Purified total RNA (500 ng) was used for RNA library preparation, according to the instructions of the Quant Seq 3’ mRNA-seq library preparation kit FWD of Illumina (Lexogen, Vienna, Austria). The RNA libraries were sequenced on an Illumina NextSeq 500 system with 75-nt-long reads. The raw data were deposited in the DNA Data Bank of Japan (DDBJ; accession nos. DRA007133, PRJDB7263).

**3’ RNA-seq data analysis**

Prior to assembly, the adapter sequences were removed from the raw reads, and the trimmed reads were assessed for quality using the FASTX toolkit (v0.0.13) software. Base trimming was performed from the 3’ end of each read to remove bases with quality below Q30 up to a minimum length of 25 bp. Reads shorter than 25 bp were removed prior to further analysis. Each read was mapped to the human genome hg38 using Strand NGS (v3.1, Agilent Technologies) and default settings. After normalization of DEseq [26] using gene expression patterns. Therefore, we compared the whole-transcriptome profiles between control iPSCs and iPSC transfectants containing HACs, with focus on the expression of pluripotent markers using 3’ RNA-seq. Total RNA was extracted from 50%-confluent cells on a 3.5-cm dish and each sample was transferred to 800 μl TRIZOL reagent (Life Technologies, Carlsbad, CA, USA). The solution was vigorously vortexed and incubated at room temperature for 5 min. The solution was then centrifuged after adding 200 μl chloroform, and the aqueous phase was carefully transferred to a new tube, following which 10 μg glycogen (Life Technologies) was added as a co-precipitant. RNA was precipitated by adding 600 μl isopropanol alcohol. The RNA pellet was washed once with 75% ethanol and then dissolved in 10 μl RNase-free water. The concentration and the quality of the RNA were verified using a Qubit fluorometer (Life Technologies) and Agilent 2100 bioanalyzer, respectively. Purified total RNA (500 ng) was used for RNA library preparation, according to the instructions of the Quant Seq 3’ mRNA-seq library preparation kit FWD of Illumina (Lexogen, Vienna, Austria). The RNA libraries were sequenced on an Illumina NextSeq 500 system with 75-nt-long reads. The raw data were deposited in the DNA Data Bank of Japan (DDBJ; accession nos. DRA007133, PRJDB7263).

**Mitotic stability**

The mitotic stability of the HAC in hiPSCs was evaluated by culturing the cells for two weeks under non-selective growth conditions. After 2-week culture in the absence of G418, spreads of metaphase chromosomes were prepared, and the presence of HACs was analyzed by FISH as described above. Specifically, the percentage of metaphase cells with HAC among a total of 50 spreads was calculated. The daily rate of HAC loss (R) was then calculated by the following formula: \( N_{14} = N_0 \times (1 - R)^{14} \), where \( N_0 \) is the number of metaphase spreads containing a HAC under selective conditions, and \( N_{14} \) is the number of metaphase spreads containing a HAC after 2 weeks of culture under non-selective conditions.

**Results**

**Efficiency of dual RMCE**

After successful insertion of the DsRed-expressing cassettes in the HAC vector by Cre-lox recombination of the lox66 site at the DsRed-expressing cassettes and the lox71 site in the gene expression cassette (Fig. 1A), we confirmed that the vector was maintained extrachromosomally in the host cell using FISH (Fig. 3). The dual RMCE activities of the three cassettes, FRT-DsRed-LoxP, Vlox-DsRed-Slox, and Vlox-DsRed-Vlox2272, were analyzed by assessing the efficiency of the replacement of a DsRed-expressing cassette, which was pre-integrated into the HAC vectors with a promoterless EGFP cassette located on an incoming vector (Fig. 1B). We did not observe the green fluorescent cells (expressing EGFP) when only the EGFP cassette was transfected. In contrast, after the EGFP cassettes and the recombinase-encoding plasmids were co-transfected, green fluorescent cells could be detected and the cells were negative for red fluorescence (Fig. 4A). Among the three cassettes tested, the Vlox-DsRed-Slox cassette showed the highest efficiency (10%) (Fig. 5). The efficiency was twice and ten times as that of the FRT-DsRed-loxP and Vlox-DsRed-Vlox2272 cassettes, respectively, and the corrected efficiency observed in the plasmid-transfected cells reached ~20%, as the estimated transfection efficiency of CMV-promoter-driven EGFP plasmid in HEK293 cells was 50–52% in each experiment. EGFP was stably expressed 3 weeks after EGFP was inserted in the HAC by dual RMCE (Fig. 4B).

**HAC transfer**

As the characteristics of cultured cells, including PSCs and established cell lines, change during prolonged culture, maintenance of cells in short passages is recommended. In fact, all transgenic mice harboring additive genes on the HAC were generated from mouse ES cells, which transferred the HAC with genes from donor cells such as CHO cells [12, 13]. Our transgenic mouse retaining multiple independent BAC transgenes possessed two consecutive gene insertions on the HAC in CHO cells following MMCT transfer into mouse ES cells [13]. We routinely conduct iMCT for HAC transfer because it is sufficient only for one 6-cm dish of 70–80% -confluent recipient cells and eight 10-cm dishes of 70–80%-confluent donor cells containing HACs. However, the transfection efficiency of plasmids in hiPSCs using transfection reagents is poor; the transfection efficiency was <5% when a CMV-promoter driven EGFP plasmid was transfected in the hiPSC line HPS0076 using FuGENE HD. Therefore, we used iMCT for HAC transfer from CHO to HEK293T cells, and we used MMCT for transfer from CHO to hiPSCs (Fig. 2B). We obtained over 20 clones per trial of iMCT for HEK293T in two trials (Fig. 6), which showed promoter-dependent DsRed expression as described previously [10] (Fig. 7). By contrast, only four clones were obtained for HAC/CMV-Vlox-DsRed-Slox (Fig. 8) and no clone for intact HAC was obtained using MMCT in two trials with hiPSCs. These results showed that our conventional MMCT method was not suitable for the stable transfection of hiPSCs, and that it is not applicable for general HAC transfer to hiPSCs. Therefore, we developed an improved MMCT for hiPSCs and successfully obtained over 20 hiPSCs harboring intact HAC in a single trial.

**Expression of control iPSCs and iPSC transfectants**

We conducted feeder-free and xeno-free culture for hiPSC expansion, and confirmed the maintenance of pluripotency during culture in the control cells and transfectants using 3’ RNA-seq for pluripotent marker genes. The KIN value of extracted total RNA of all samples was ≥9. 3’ RNA-sequencing generated 11,115,860 raw reads from five RNA samples using the Illumina NextSeq platform, with approximately 2.2 million reads.
reads per sample (Table 1). After discarding adapters and low-quality reads from the raw data, 7,562,155 clean reads (68.0%) were obtained, 90.1–91.6% of which were mapped to the hg38 human genome. Scatter plots of the normalized 3' RNA-seq expression data showed high correlation between control iPSCs and all four iPSC transformants ($R^2 > 0.93$) (Fig. 9). Furthermore, the pluripotent stem cell markers OCT3/4, SOX2, NANOG, and SSEA1 were expressed in control iPSCs and four iPSC transformants (Supplementary Table S1), whereas the HAC-selectable gene encoding neomycin resistance was expressed in all iPSC transformants but not in control iPSCs (data not shown).

**Mitotic stability of the HACs**

We examined the mitotic stability of HAC in the four clones used in the 3’ RNA-seq experiments using FISH. After 2 weeks without selection, 100%, 98%, 96%, and 100% of the metaphase cells in hiPSC/HAC#1, hiPSC/HAC#2, hiPSC/HAC#3, and hiPSC/HAC#4 retained the HAC, respectively, and the number of HAC copies per cell was maintained at one under non-selective conditions. The daily rate of HAC loss was 0%, 0.14%, 0.29%, and 0% for hiPSC/HAC#1, hiPSC/HAC#2, hiPSC/HAC#3, and hiPSC/HAC#4, respectively. No integration of the HAC into host chromosomes was observed in any cell line. These results indicated that the HAC can be maintained stably in hiPSCs.

**Discussion**

We successfully transferred a HAC from donor cells into hiPSCs using MMCT. This represents the first report of HAC transfer into hiPSCs. To date, two methods for generating HAC-containing hiPSCs have been reported. The first method developed by Oshima’s group involved constructing a HAC with a complete 2.4-Mb genomic dystrophin sequence (DYS-HAC)
followed by transformation in DT40 and CHO cells [27]. The DYS-HAC was transferred to Duchenne muscular dystrophy patient-derived fibroblasts from CHO cells, from which iPSCs were generated using a combination of lentiviral infection for expressing mouse SLC7A1 and retroviral infection for expressing KLF4, SOX2, OCT4, and c-MYC [28]. The other method involved de novo HAC generation in ES cells using HSV-1 amplicon technology [29]. In contrast, we succeeded in directly transferring the HAC with limited genes to hiPSCs. The proposed transfer method can become a superior approach for the research and application of established pluripotent cell lines, such as in drug discovery, toxicity testing, disease modeling, and gene therapy. Furthermore, the efficiency of the HAC transfer in hiPSCs via MMCT was sufficiently increased to be applicable to any iPSC line; indeed, we have already successfully achieved HAC transfer with two other hiPSC lines (unpublished data). Importantly, strong correlations between gene expression levels were observed between control iPSCs and the iPSC transformants.

There are significant differences between our MMCT method and that used by Liskovykh et al. [21]. The first difference involves the microcell collection after micronucleation. In our method, the microcell was centrifuged in cell culture medium mixed with Percoll, whereas Liskovykh and colleagues performed this step in only the cell culture medium. The second difference lies in the reagent used for the fusion of microcells and recipient cells. We used PEG1500, whereas Liskovykh and colleagues used the HVJ envelope cell fusion kit (Cosmo Bio Ltd.,

Figure 4: HEK293 cells after dual recombinase-mediated cassette exchange (RMCE). (A) Two days after dual RMCE. (B) Three weeks after dual RMCE. Two colonies originated from two cells: one was intact (DsRed) and the other was cassette-exchanged (EGFP).

Figure 5: Efficiency of dual recombinase-mediated cassette exchange. The blue bars show the mean value of three experiments; the error bars indicate SD.
Japan). However, since the efficiency of their basal MMCT was similar to that of our usual MMCT method, we changed only one common reagent for the improved method to induce micronucleation: colcemid to TN-16 and griseofulvin. This change significantly increased the efficiency of HAC transfer to recipient cells in three different human cell lines by ~3.7-fold [21]. Moreover, the advantages of iMCT include the use of small amounts of recipient and donor cells and lack of host cell limitation. We previously reported the successful transfer of a HAC vector containing the human beta globin gene cluster from K562 cells to HT1080 or HeLa cells by iMCT, and the expression of the Gc- and Ac-globin genes from the HAC was activated in transformed K562 cells and was reproducibly repressed in non-erythrocyte cell lines (HeLa and K562) [24]. It is likely that we selected the appropriate donor cells for HAC vector transformation; in other words, iMCT or MMCT should be used for HAC vector transfer in hiPSCs depending on the purpose. Currently, certain commercial transfection reagents with high efficiency of plasmid transfection in hiPSCs and hES cells are available. We intend to use these reagents for HAC vector transfer in hiPSCs via iMCT. Nevertheless, we are in the process of testing the application of a HAC vector for gene therapy, especially for genetic disorders, using disease-specific hiPSCs.

**Figure 6:** FISH analysis of HEK293T cells after isolated mitotic chromosome transfection of a human artificial chromosome. FISH analysis was performed using the alphoid probe (green) and BAC (red) (see details in the section “Materials and Methods”). The HAC is indicated by the yellow triangle.

**Figure 7:** DsRed expression levels from the HAC in HEK293T cells. (A) CMV promoter-driven expression of DsRed. (B) EF1 promoter-driven expression of DsRed.

Dual RMCE of VCre/VloxP and SCre/SloxP systems with the VloxP-DsRed-SloxP cassette (VDS) showed the highest efficiency (20% of the plasmid-transfected cells) in this study. This efficiency was approximately half that obtained by Anderson et al. [19], who observed that the FRT-DsRed-LoxP cassette (FDL) yielded the maximum transformation efficiency. They further reported that the efficiency of FDL was twice as high as that of the LoxP-DsRed-FRT cassette (LDF). As generation of FDL in a HAC vector is difficult because of the construction of the HAC gene insertion cassette (Fig. 1A), we tested LDF, VDS, and the VLoxP-DsRed-VLoxP2272 cassette in HAC in this study. The efficiency of VDS was twice as high as that of LDF under similar conditions, and the dual RMCE efficiency of VDS was almost equal to that of FDL. One of the possible reasons for the differences between the two results may be related to the different characteristics of the cells used between studies, that is, CHO cells versus HEK293 cells (this study). Nevertheless, this high
Figure 8: Human iPSCs after microcell-mediated chromosome transfer of human artificial chromosome. (A) FISH analysis. The HAC is labeled green (alphoid probe) and red (BAC probe) and is indicated by a yellow triangle. An arrowhead shows the HAC. (B) Phase-contrast image.

Table 1: Summary of 3' RNA-seq data analysis.

| Sample ID   | Sample name          | Raw reads   | Clean reads  | Mapped reads |
|-------------|----------------------|-------------|--------------|--------------|
| CR18003-1   | Control hiPSC (HPS0076) | 2,255,004   | 1,595,266    | 1,453,559    |
| CR18003-2   | hiPSC/HAC #1         | 2,309,650   | 1,518,786    | 1,371,336    |
| CR18003-3   | hiPSC/HAC #2         | 2,095,731   | 1,456,552    | 1,312,358    |
| CR18003-4   | hiPSC/HAC #3         | 2,065,626   | 1,468,999    | 1,326,291    |
| CR18003-5   | hiPSC/HAC #4         | 2,389,849   | 1,522,552    | 1,394,054    |

Figure 9: 3' RNA-seq expression scatterplots between two representative samples of control hiPSCs and hiPSCs containing HACs. The plot is on a log2-transformed scale.
transfection efficiency enabled us to perform a screening experiment for many cells expressing single copies of the genes of interest in one cell per trial of transfection; in addition, stable transfectants could be generated in the absence of drug selection. We are planning to conduct functional screening analyses with many mutants of disease-associated genes to express the genes in human disease-specific iPSCs using HAC-containing VDS cassettes. Furthermore, we are developing a screening system for genetic interaction using abundant KAZUSA cDNA and Halo-tag clones, as the combination of HAC technology and Halo-tag clones was reported to be successful for centromere chromatin assembly [30]. Moreover, the Vlox-Slox cassette system can be applied for integration in the host genome, and we have already generated HEK293 cells containing one CMV-Vlox-DeRed-Slox cassette at the AAVS1 safe harbor site using specific TALEN-mediated homologous recombination.

In conclusion, we believe that HAC vectors will offer an effective transgene expression system in human iPSCs.

**Supplementary data**

Supplementary data are available at Biology Methods and Protocols online.

**Acknowledgements**

The authors thank T. Hosouchi, T. Watanabe, and Y. Yamanaka for providing excellent technical support.

**Funding**

This work was supported by JSPS KAKENHI [JP25640108 to Y.H., 15K06927 to Y.H.], the Project for Developing Innovation Systems, and the Program for Fostering Regional Innovation [to O.O.].

Conflict of interest statement. None declared.

**REFERENCES**

1. Mali P, Cheng L. Concise review: human cell engineering: cellular reprogramming and genome editing. Stem Cells 2012;30:75–81.
2. Lyu C, Shen J, Wang R et al. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Stem Cell Res Ther 2018;9:92.
3. Kim SI, Matsumoto T, Kagawa H et al. Microhomology-assisted scarless genome editing in human iPSCs. Nat Commun 2018;9:399.
4. Wu M, Liu S, Gao Y et al. Conditional gene knock out and reconstitution in human iPSCs with an inducible Cas9 system. Stem Cell Res 2018;29:6–14.
5. Oceguera-Yanez F, Kim SI, Matsumoto T et al. Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives. Methods 2016;101:43–55.
6. Castano J, Bueno C, Jiménez-Delgado S et al. Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the “safe harbor” AAVS1 locus. Stem Cell Res 2017;21:137–40.
7. Mills W, Critcher R, Lee C et al. Generation of an approximately 2.4 Mb human X centromere-based minichromosome by targeted telomere-associated chromosome HAC|e44. Nucleic Acids Res 2010;38:e33.
8. Ikenn M, Masumoto H, Okazaki T. Distribution of CENP-B boxes reflected in CREST centromere antigenic sites on long-range alpha-satellite DNA arrays of human chromosome 21. Hum Mol Genet 1994;3:1245–57.
9. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010;11:R106.
27. Hoshiya H, Kazuki Y, Abe S et al. A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene. Mol Ther 2009;17:309–17.

28. Kazuki Y, Hiratsuka M, Takiguchi M et al. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther 2010;18:386–93.

29. Mandegar MA, Moralli D, Khoja S et al. Functional human artificial chromosomes are generated and stably maintained in human embryonic stem cells. Hum Mol Genet 2011;20:2905–13.

30. Ohzeki J, Shono N, Otake K et al. KAT7/HBO1/MYST2 regulates CENP-A chromatin assembly by antagonizing Suv39h1-mediated centromere inactivation. Dev Cell 2016;37:413–27.